Analyst Price Target is $21.00
▲ +191.67% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Alpine Immune Sciences in the last 3 months. The average price target is $21.00, with a high forecast of $25.00 and a low forecast of $17.00. The average price target represents a 191.67% upside from the last price of $7.20.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in Alpine Immune Sciences. This Buy consensus rating has held steady for over two years.
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.